Nabriva Therapeutics plc (NBRVF)
OTCMKTS: NBRVF · Delayed Price · USD
0.0001
0.00 (0.00%)
Jul 9, 2024, 9:30 AM EDT - Market closed
Nabriva Therapeutics Employees
Nabriva Therapeutics had 39 employees as of December 31, 2022. The number of employees decreased by 34 or -46.58% compared to the previous year.
Employees
39
Change (1Y)
-34
Growth (1Y)
-46.58%
Revenue / Employee
$757,872
Profits / Employee
-$1,411,641
Market Cap
300.00
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
NBRVF News
- 8 days ago - Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics - Business Wire
- 1 year ago - Nabriva Therapeutics Provides Corporate Update - GlobeNewsWire
- 1 year ago - Nabriva's stock is up after sharing antibiotic news - Market Watch
- 1 year ago - Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis - GlobeNewsWire
- 1 year ago - Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022 - GlobeNewsWire
- 2 years ago - Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split - GlobeNewsWire
- 2 years ago - Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - GlobeNewsWire